Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Operating Leases: 2021-2024

Historic Operating Leases for 4D Molecular Therapeutics (FDMT) over the last 4 years, with Dec 2024 value amounting to $19.0 million.

  • 4D Molecular Therapeutics' Operating Leases fell 16.08% to $16.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.6 million, marking a year-over-year decrease of 16.08%. This contributed to the annual value of $19.0 million for FY2024, which is 64.63% up from last year.
  • According to the latest figures from FY2024, 4D Molecular Therapeutics' Operating Leases is $19.0 million, which was up 64.63% from $11.5 million recorded in FY2023.
  • Over the past 5 years, 4D Molecular Therapeutics' Operating Leases peaked at $19.0 million during FY2024, and registered a low of $11.5 million during FY2023.
  • Moreover, its 3-year median value for Operating Leases was $13.5 million (2022), whereas its average is $14.7 million.
  • Its Operating Leases has fluctuated over the past 5 years, first decreased by 14.46% in 2023, then soared by 64.63% in 2024.
  • Over the past 4 years, 4D Molecular Therapeutics' Operating Leases (Yearly) stood at $15.2 million in 2021, then fell by 11.49% to $13.5 million in 2022, then decreased by 14.46% to $11.5 million in 2023, then surged by 64.63% to $19.0 million in 2024.